Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer

Table 3

The relationship between SCCA, NSE, CEA, and CYFRA21-1 and the clinicopathological factors (ng/mL, 𝑥±𝑠).

Clinicopathological characteristics	𝑁	SCCA	NSE	CEA	CYFRA21-1
Histological classification
Adenocarcinoma	68	0.22±0.26	17.95±8.30	30.76±46.78^∗	4.00±3.76
Squamous cell lung cancer	56	3.79±5.56^∗	16.83±5.66	4.49±2.49	10.34±9.38^∗
Small cell lung cancer	8	0.15±0.07	50.80±22.60^∗	1.81±1.05	1.31±0.30
NSCLC TNM stage
I/II	73	2.59±4.92	15.21±4.53	7.44±8.36	7.32±9.01
III/IV	51	0.70±1.03	21.94±19.15	33.71±50.04^∗	5.65±3.99
SCLC stage
Limited disease (LD)	3	2.06±1.87	23.43±16.74	7.27±6.12	7.11±5.23
Extensive disease (ED)	5	0.86±0.79	25.02±10.90	33.51±29.63^∗	5.92±3.80

P value was calculated by Student’s t-test ∗P < 0.05.